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Abstract
Purpose There are indications that a history of allergy
may offer some protection against cancer. We studied the
relation of three objectively determined allergy markers
with cancer mortality and hospitalization risk.
Methods Associations between three allergy markers
(number of peripheral blood eosinophil counts, skin test
positivity, and serum total IgE) with mortality and hospi-
talization from any type and four common types of cancer
(lung, colorectal, prostate, and breast cancer) were assessed
in the Vlagtwedde–Vlaardingen cohort (1965–1990), with
follow-up of mortality until 31 December 2008. Hospital-
ization data were available since 1 January 1995.
Results There were no significant associations between
objective allergy markers and cancer mortality or hospitaliza-
tion. We found several associations in specific subgroups. A
higher number of eosinophils was associated with a decreased
risk of colorectal cancer mortality in ever smokers HR (95 %
CI) = 0.61 (0.45–0.83) and in males 0.59 (0.42–0.83); how-
ever, no overall association was observed 0.84 (0.64–1.09).
Skin test positivity was associated with a decreased risk of any
cancer mortality only among females 0.59 (0.38–0.91) and
showed no overall association 0.83 (0.67–1.04). Serum total
IgE levels were associated with an increased risk of lung cancer
mortality among females 4.64 (1.04–20.70), but with a
decreased risk of cancer hospitalization in ever smokers 0.77
(0.61–0.97) and males 0.72 (0.55–0.93); however, no overall
associations were observed [mortality 0.99 (0.79–1.25), and
hospitalization 0.86 (0.71–1.04)].
Conclusions We found no associations between objective
allergy markers and cancer in the total population. How-
ever, skin test positivity and a high number of eosinophils
were associated with a reduced risk to die of cancer in
specific subgroups. Hence, it seems important to study
specific subgroups defined by gender and smoking habits in
order to identify allergy markers of predictive value for
cancer mortality.
Keywords Cancer mortality  Cancer hospitalization 
Eosinophils  IgE  Skin test positivity
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Introduction
There are indications of an inverse association between a
history of allergy and cancer [1–3], suggesting that aller-
gies may offer some protection against cancer in general.
Subjects with allergy have a hyperactive immune system.
The fact that the immune system can continually recognize
and remove malignant cells might explain such a protective
effect of allergy on cancer development [1]. Although an
appealing theory, the strength of the evidence in favor of
this so-called immune surveillance theory is limited.
Studies on the association between allergy and cancer show
inconsistent results, mainly because the association
between allergy and cancer is complex and is based on both
different types of cancer and different definitions of allergy
[3].
Thus, some studies have reported a negative association
between allergy and cancer, supporting the immune sur-
veillance theory [1–3], while others show a positive [5, 6]
or no general association [4]. A theory that is often used to
explain increased risk of specific cancers associated with
allergy is the ‘antigenic stimulation theory.’ It suggests that
inflammatory conditions associated with allergic diseases
may induce the oxidative damage, resulting in tumor sup-
pressor gene mutations in proteins involved in DNA repair
or apoptotic control, thus may increase the development of
cancer [7, 8]. Besides the above-mentioned mechanism,
there is an emerging evidence for an important role of
T-helper 2 (TH2) immune skewing in the association
between allergy and cancer [8].
Recent reviews showed that the association between
allergies and cancer is organ or site specific [6]. Several
studies indicated that the presence of allergy markers was,
for example, associated with a decreased risk of colorectal
cancer, pancreatic cancer, and larynx cancer, but with
increased risks of lymphoma, prostate cancer, and mye-
loma, and there are inconsistent results for breast cancer
and lung cancer [6, 8, 9].
However, many unanswered questions remain about the
inconsistently reported associations between allergy and
cancer risk. Few studies have reported whether the asso-
ciations between allergy and cancer risk vary according to
gender or smoking habits [8]. For instance, Hsiao et al. [10]
found an inverse association between allergies and head
and neck cancer, particularly among males and smokers.
However, no clear explanation for the gender difference
has been proposed. Thus, future studies are needed to
clarify the role of smoking and gender in the association
between allergy and different cancer types.
We studied in a general population sample in two Dutch
communities (Vlagtwedde–Vlaardingen) whether allergy is
associated with cancer mortality and hospitalization (as
proxies for cancer incidence) after adjustment for potential
confounders. We also assessed the possible effect modifi-
cation of gender and smoking on the association between
allergy and cancer since previous studies suggested these
might have differential effects [2, 11].
Methods
Ethics statement
The Committee on Human Subjects in Research of the
University of Groningen reviewed the study and affirmed
the safety of the protocol and study design and specifically
approved this study. All participants gave their written
informed consent.
Study population
We studied objective allergy markers, cancer mortality and
hospitalization using the Vlagtwedde–Vlaardingen cohort
study. The Vlagtwedde–Vlaardingen study was set up as a
general population-based cohort study on the epidemiology
of pulmonary diseases in exclusively Caucasian individuals
of Dutch descent [12, 13]. This study started in 1965 and
participants had medical examinations every 3 years until
the last survey in 1989/1990. In Vlaardingen, only partic-
ipants who were included at baseline (1965 or 1969) were
approached for follow-up, whereas in Vlagtwedde new
subjects aged between 20 and 65 were invited to participate
at every survey. We updated the vital status of all partici-
pants on 31 December 2008 and evaluated five main cancer
mortality outcomes, i.e., mortality from all types of cancer,
lung, colorectal, prostate, and breast, either as primary or
secondary cause of death. The causes of death were coded
according to the International Classification of Diseases
(ICD). Hospitalization data since 1 January 1995 were
obtained using probabilistic matching based on date of
birth, gender, and postal code. The probabilistic matching
method was used because of privacy regulations. A match
was defined if date of birth, gender, and postal code in our
source-file (the Vlagtwedde–Vlaardingen cohort data) were
exactly equal to those in the hospital admission registry
file. Diagnosis at discharge was used to identify the reason
for the hospitalization. The endpoints used for the current
study were having at least one hospitalization due to any
cancer or due to a specific type of cancer (i.e., lung,
colorectal, prostate, and breast cancer). Subjects who were
lost to follow-up or died within 2 years after the start of the
hospitalization data (in 1995) and who were not hospital-
ized during these years were excluded from these analyses.
However, subjects with a shorter registration period but
with a hospital admission for cancer in this period are
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included in the group ‘at least one hospitalization due to
any cancer.’
Population characteristics
We collected data on age, gender, and smoking habits
using the Dutch version of the British Medical Research
Council questionnaire [12, 13]. We used the data of a
subject’s first available survey. We defined smoking habits
as follows: Never smoker and ever (i.e., ex and current)
smoker (including pipe/cigar smokers).
The body mass index (BMI) was calculated as weight in
kilograms divided by the square of the height in meters (kg/m2).
Allergy
Peripheral blood eosinophil counts were assessed in a 1:11
dilution of peripheral blood with a Bu¨rker counting
chamber [12, 13].
Skin prick tests were performed at the first available survey.
Four common aeroallergens (house dust, mixed pollen, epi-
dermal products, and mixed molds) were applied intracutane-
ously to the forearm (Diephuis, Groningen, the Netherlands)
[14]. Wheal diameters for each allergen were measured to the
nearest half millimeter and coded on a six-point scale (0 =
0–5.0 mm,1 C 5.0–7.5 mm,2 C 7.5–10.0 mm,3 C 10.0–12.5 mm,
4 C 12.5 mm, 5 C 15.0 mm). Scores for the four allergens
were added to a skin test sum score (minimum 0, maximum
20). Skin test positivity was defined as a skin test sum score
C3 [15].
Serum total Immunoglobulin E (IgE) was determined at
only one survey, i.e., the final survey, with the CAP system
(Pharmacia, Woerden, the Netherlands) and expressed in
kU/L [15].
Cancer mortality and hospitalization
Cancer was classified according to the ICD-coding system:
Any type of cancer (ICD 7: 140–239 and 294; ICD 8:
140–239; ICD 9: 140–239 and 288; ICD10: C00-C97, D00-
D48), lung cancer (cancer of trachea, bronchus, and lung)
(ICD 7: 162, 163; ICD 8: 162, 163; ICD 9: 162, 163, 165;
ICD10: C33, C34, C38, C39), cancer of colon and rectum
(further referred to as colorectal cancer) (ICD 7: 153, 154;
ICD 8: 153, 154; ICD 9: 153, 154; ICD 10 C18-C21),
breast cancer (ICD 7: 170; ICD 8: 174; ICD 9:174, 175 and
ICD10: C50), and prostate cancer (ICD 7: 177; ICD 8: 185;
ICD 9: 185 and ICD 10: C61).
Statistical analyses
Descriptive analyses of the subject characteristics and the
mortality and hospitalization data were performed.
Differences between groups were tested with independent
samples t test and Chi-square test for continuous and cat-
egorical variables, respectively. Blood eosinophil counts
and serum total IgE were log-transformed to obtain nor-
mality of the distribution. Multivariate Cox regression (for
mortality) and logistic regression (for hospitalization) with
adjustment for age, gender, Forced Expiratory Volume in
1 s (FEV1) as % of predicted, BMI (all at the first survey),
and place of residence were used to estimate the effect of
the allergy markers on the cancer outcomes. To determine
whether the association of the three allergy markers was
different for males and females, or for ever and never
smokers, stratified analyses were performed, and interac-
tions between allergy markers and gender, or smoking were
tested. In the Cox regression analyses, censoring took place
when the subjects were still alive, were lost to follow-up, or
died of causes other than cancer or the specific cancer
under study [16]. Time was defined from the first available
survey until cancer mortality or until censoring in the
analyses of eosinophils and skin test positivity. Similarly,
in the analyses of IgE, time was defined from the only
available survey, i.e., the final survey, until cancer mor-
tality or until censoring. Finally, to investigate the robust-
ness of our results, we conducted several sensitivity
analyses. All analyses were performed at Statistics Neth-
erlands (The Hague, the Netherlands). p values\0.05 (two
sided) were considered to be statistically significant.
Results
Mortality
Among all 8,465 subjects, 4,505 (53.2 %) were alive, 1,194
(14.1 %) died due to cancer, 2,473 (29.2 %) died due to
another reason than cancer, 158 subjects (1.9 %) died due to
external causes such as an accident, suicide or homicide, in
13 (0.1 %) subjects the cause of death could not be deter-
mined, and 122 (1.5 %) subjects were lost to follow-up
(Table 1). Of those subjects who died due to cancer, most
died of lung cancer (n = 275, 23.0 %), followed by colo-
rectal cancer (n = 134, 11.2 %), prostate cancer (n = 83,
7.0 %), and breast cancer (n = 117, 9.9 %) (Fig. 1).
Details on the associations between allergy markers and
baseline characteristics of the subjects in 1965/1967/1969
and vital status in 2008 are presented in the Online
Resource Tables 1 and 2, respectively.
Among all 8,465 subjects, 7,085 (83.7 %) subjects had
data available on peripheral blood eosinophil counts and on
all included covariates, 6,193 (73.1 %) had data available
on skin test positivity and on all included covariates, and
for 2,324 (27.5 %) subjects, data on IgE and on all included
covariates could be obtained (Online Resource Table 3).
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Subjects who died due to cancer were more often men,
older, had a higher BMI, were more often smokers, and
had a lower FEV1 % predicted at the first survey than
those who were alive. Subjects who died due to cancer
had a higher level of peripheral blood eosinophils com-
pared with subjects who were alive. Subjects who died
due to cancer had less skin test positivity compared with
subjects who were alive (p = 0.001). There were no
significant differences in the level of serum total IgE
between subjects who died due to cancer and those who
were alive (Table 1).
Hospitalization
Of the total number of 8,465 subjects, 6,174 subjects were
successfully matched to the hospital admission file (in 20
subjects, a successful match could not be found, and 2,271
subjects were lost to follow-up or died before the start of
registration of hospitalization in 1995). Of these 6,174
subjects, we excluded 91 subjects because they had a fol-
low-up period shorter than 2 years and no hospital
admission in these 2 years after the start of registration of
hospitalization (Fig. 1). Among all 6,083 subjects with data


























All subjects (%)a 53.2 14.1 29.3 1.9 1.5
Male (%) 48.8 58.3 54.8 63.9 57.4 0.00 0.04
Age (years) [mean (SD)] 30.2 (10.2) 45.9 (11.1) 50.1 (9.6) 43.6 (13.7) 33.2 (13.3) 0.00 0.00
Smoking (%)
Never smoker 38.0 33.2 39.8 35.9 38.8 0.00 0.00
Ever smoker 62.0 66.8 60.2 64.1 61.2
FEV1 % of predicted
b
[mean (SD)]
90.4 (12.4) 85.2 (14.6) 82.9 (16.7) 87.2 (13.2) 89.6 (12.1) 0.00 0.00
BMI (kg/m2) (%)
\25 60.9 39.4 32.4 50.8 64.7
25–30 31.8 44.7 49.5 37.9 29.3 0.00 0.00




2.3 (0.8) 2.4 (0.7) 2.5 (0.7) 2.3 (0.9) 2.4 (0.9) 0.00 0.52
Skin test positivity (%) 18.9 9.9 9.5 13.6 27.1 0.00 0.71
Serum total IgE (kU/L)
(Log 10), mean (SD)c




39.2 (19.2–44.2) 26.8 (0.5–43.2) 26.9 (0.2–43.2) 19.6 (0.2–42.8) 22.8 (0.0–41.0) 0.00 0.36
Follow-up time for skin
test positivity in years,
median (range)d
39.2 (36.2–44.2) 27.4 (0.5–43.2) 27.6 (0.2–43.2) 12.1 (0.2–42.8) 26.2 (0.0–41.0) 0.00 0.85
Follow-up time for serum
total IgE in years,
median (range)d
19.2 (18.2–19.2) 11.8 (0.6–19.2) 12.8 (0.4–19.2) 13.3 (2.0–18.7) 12.2 (1.1–18.7) 0.00 0.21
Place of residence (%)
Vlagtwedde 66.7 63.8 69.5 72.8 55.7 0.09 0.00
a All subjects: n = 8,452; in 13 subjects, the cause of death could not be determined
b FEV1 % of predicted, percentage of predicted forced expiratory volume in 1 s
c IgE was measured at the last survey in 1989/1990
d The follow-up time for allergy markers were calculated as the difference between the age at the first available allergy markers measurement
and the age at last known vital status
e p value calculated by Chi square or t test
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on hospitalization, 1,022 (16.8 %) subjects were hospital-
ized for any type of cancer. Subjects, who had at least one
hospitalization due to cancer were significantly older, were
more often smokers, had a higher BMI, and had a lower
FEV1 % predicted compared with subjects who had no
hospitalization. Subjects with at least one hospitalization
due to cancer were less often skin test positive compared
with subjects who had no hospitalization (p = 0.02).
Subjects with at least one hospitalization due to cancer
were older compared with subjects who had at least one
hospitalization but not due to cancer (p = 0.03). There
were no significant differences in the level of eosinophils,
and the level of serum total IgE, between subjects who had
at least one hospitalization for any type of cancer and those
who were not hospitalized at all or those who were hos-
pitalized but not due to cancer (Table 2).
Among all 6,083 subjects with data on hospitalization,
5,449 (89.6 %) subjects had data available on peripheral
blood eosinophil counts and on all included covariates,
4,611 (75.8 %) had data on skin test positivity and on all
included covariates, and 2,299 (37.8 %) subjects had data
on IgE and on all included covariates (Online Resource
Table 3).
Peripheral blood eosinophil counts
In the total population, we found no significant association
between number of eosinophils and cancer mortality or
cancer hospitalization (Table 3; Fig. 2a). A higher number
of eosinophils was significantly associated with decreased
risk of colorectal cancer mortality in ever smokers (Hazard
ratio (HR) (95 % confidence interval (CI)) = 0.61
(0.45–0.83); see Table 4) and males (0.60 (0.42–0.83);
Table 5) (Online Resource Figure 1 and 2). The interaction
between the number of eosinophils and smoking and gen-
der was significant. To assess whether this association is
gender or smoking dependent, we investigated the inter-
action between eosinophils and smoking separately in
males and females and the interaction between eosinophils
and gender separately in never and ever smokers. We
observed a significant interaction between eosinophils and
ever smoking within males and a significant interaction
between eosinophils and male gender within ever smokers
(Online Resource Table 4). There were no significant
interactions between number of eosinophils and gender or
smoking in the analyses on hospitalization due to cancer
(Online Resource Table 5).
Skin test positivity
Skin test positivity was not associated with cancer mor-
tality or cancer hospitalization in the total population
(Table 3; Fig. 2b). Within females, skin test positivity was
associated with a decreased risk of mortality from any type
of cancer (0.59 (0.38–0.91); Table 5), and the interaction
between skin test positivity and gender on any type of
Fig. 1 Flow diagram showing the Vlagtwedde–Vlaardingen study design
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cancer mortality was significant. There were no significant
interactions between skin test positivity and gender on any
type of cancer hospitalizations (Online Resource Table 6).
Serum total IgE
Serum total IgE was not associated with cancer mortality or
cancer hospitalization in the total population (Table 3;
Fig. 2c). The association between total IgE and cancer
mortality risk was not significantly different between ever
and never smokers (Table 3). The association between
serum total IgE and cancer mortality risk was significantly
different between males and females, with a significantly
increased risk of mortality from lung cancer among
females (4.64 (1.04–20.70)) (Table 4). Higher levels of
serum total IgE were associated with a lower chance of
hospitalization for all types of cancer among males (0.76
(0.59–0.98) (Online Resource Table 6).
Sensitivity analyses
A sensitivity analysis on cancer mortality, excluding the
subjects who were lost to follow-up or died within 2 years
of the visit with the assessment of the allergy marker
[(eosinophils: total n = 44, cancer mortality n = 10), (skin
test positivity: total n = 41, cancer mortality n = 7), and
(total IgE: total n = 30, cancer mortality n = 12)], gave
similar results as the main analysis (results not shown).
Table 2 Characteristics at first survey of subjects according to hospitalization status
Characteristics No
hospitalization
(n = 1,750) (NA)
At least one hospitalization
for any type of cancer
(n = 1,022) (CA)
At least one hospitalization
but not due to cancer







Age on 1 January 1995 (years) [mean (SD)] 54.2 (12.0) 61.7 (11.7) 60.5 (12.4) 0.00 0.00
Male (%) 46.9 51.3 48.8 0.03 0.16
Smoking (%)
Never smoker 41.2 33.0 38.3 0.00 0.00
Ever smoker 58.8 67.0 61.7
FEV1 % of predicted
a [mean (SD)] 90.2 (12.1) 88.2 (13.6) 89.4 (13.1) 0.00 0.01
BMI (kg/m2) (%)
\25 67.5 46.5 51.1
25–30 26.1 41.9 38.7 0.00 0.04
[30 6.4 11.6 10.2
Eosinophil count (*11 cells/ll)
(Ln) [mean (SD)]
2.4 (0.8) 2.4 (0.8) 2.4 (0.8) 0.74 0.75
Skin test positivity (%) 19.5 15.5 16.2 0.02 0.65
Serum total IgE (kU/L) (Log 10) at
visit 1989/1990 [mean (SD)]
1.5 (0.6) 1.4 (0.6) 1.4 (0.6) 0.09 0.23
Place of residence (%)
Vlagtwedde 63.0 65.6 69.0 0.17 0.04
Hospitalization registry data were available for 6,083 subjects (3,125 females and 2,925 males)
a FEV1 % of predicted, percentage of predicted forced expiratory volume in 1 s
b p value calculated by Chi-square or t test
Table 3 Hazard ratio of allergy markers for mortality, and odds ratios of allergy markers for hospitalization from any and specific type of cancer
Any cancer Lung cancer Colorectal cancer Prostate cancer Breast cancer
Cancer mortality HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI) HR (95 % CI)
Eosinophils (ln) 1.05 (0.96–1.15) 1.11 (0.92–1.34) 0.84 (0.64–1.09) 1.02 (0.71–1.46) 0.86 (0.66–1.13)
Skin test positivity 0.83 (0.67–1.04) 0.90 (0.58–1.40) 1.20 (0.65–2.24) 0.69 (0.24–1.94) 0.57 (0.25–1.31)
Total IgE (log10) 0.99 (0.79–1.25) 1.03 (0.62–1.71) 0.99 (0.52–1.91) 0.59 (0.26–1.36) 0.48 (0.15–1.49)
Cancer hospitalization OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI) OR (95 % CI)
Eosinophils (ln) 0.99 (0.90–1.08) 1.17 (0.89–1.54) 1.05 (0.80–1.39) 0.98 (0.72–1.33) 0.98 (0.75–1.29)
Skin test positivity 0.98 (0.79–1.21) 0.74 (0.40–1.38) 0.78 (0.41–1.49) 1.19 (0.65–2.18) 1.03 (0.53–1.98)
Total IgE (log10) 0.86 (0.71–1.04) 0.89 (0.52–1.54) 0.92 (0.56–1.49) 0.82 (0.49–1.38) 0.88 (0.48–1.64)
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In addition, we performed separate analyses on cancer
as primary cause of death and as secondary cause of death.
The results of these analyses were comparable to the results
of the presented analyses where we analyzed cancer as
either the primary or secondary cause of death (results not
shown). Since FEV1 could be on a causal path from allergy
to cancer mortality, we performed a sensitivity analyses
excluding FEV1 from our Cox regression model. These
analyses gave the same results as our main analyses (results
not shown).
The different inclusion strategy of Vlagtwedde and
Vlaardingen may introduce bias. We, therefore, stratified
our analyses by place of residence. In addition, we per-
formed a meta-analysis with these two studies and dem-
onstrated evidence of association between both datasets.
The meta-analysis showed the same result as the original
pooled analysis (results not shown).
Furthermore, additional adjustment for years of
recruitment gave the same results as our main analyses
(results not shown).
Discussion
This is the first large cohort study that investigated three
objective markers of allergy, mortality and hospitalization
due to cancer in the general population. We found no
association between allergy and the risk to die of cancer or
hospitalization in the total population. However, in specific
subgroups, we did find such associations: Higher numbers
of eosinophils were associated with a reduced risk of
colorectal cancer mortality among ever smokers and males.
The effect of skin test positivity on the risk of mortality
from all types of cancer was different for males and
females, and we found a negative association among
females. The effect of IgE on lung cancer mortality risk
was different for males and females; we found a positive
association among females. Higher levels of serum total
IgE showed to be protective against all types of cancer
hospitalizations among males and ever smokers.
The findings of the current study corroborate the find-
ings of previous work in this field; especially those who
found no general association between allergy and cancer,
with the same definition of allergy as we used [17–20], or
based on a self-reported history of allergy [21]. Results of
previous studies were inconsistent. This type of discrep-
ancy between results among studies is understandable,
mainly because the association between allergies and
cancer is complex and is based on both different types of
cancer [5] and different definitions of allergy [8, 11].
Studies vary considerably in their definitions of allergy and
allergy markers. For instance, very few studies distinguish
between atopy [type-I allergy, IgE-mediated hypersensi-
tivity] and allergy [immune hypersensitivity, regardless of
the mechanism] [11].
Although immune surveillance and antigen stimulation
are the most established hypotheses for explaining the
Fig. 2 Hazard ratio of eosinophils (a), skin test positivity (b), and
IgE (c) for mortality and Odds ratio for hospitalization from cancer
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association between allergy and cancer, the body of current
worldwide literature provides limited support for these two
hypotheses [19].
We found that high numbers of peripheral blood
eosinophils are protective against colorectal cancer mor-
tality only in males and ever smokers. In-depth analyses
showed that a decreased risk of mortality from colorectal
cancer is associated with a high number of eosinophils
within males who were smokers (Online Resource
Table 4). This observation may be explained by the fact
that in our study population, smokers and males had a
higher number of eosinophils compared with females and
non-smokers, suggesting a threshold effect. This means
that the protective effect of eosinophils on cancer only
becomes apparent given a certain minimal level of eosin-
ophils. However, an exploratory analysis in which we
divided the eosinophil levels into equally spaced categories
showed no evidence of this threshold effect (Online
Resource Table 7).
Another explanation may be that although higher num-
bers of blood eosinophils are an important aspect of
allergy, in smokers, eosinophil levels may be a better
indicator of general inflammation rather than allergic
inflammation. Earlier results in the Vlagtwedde–Vlaardin-
gen cohort indeed showed within smokers the relationship
between eosinophils and allergy is weaker than in non-
smokers [22]. Since general inflammation is a risk factor
for many other diseases (such as cardiovascular disease)
[23] it is very well possible that these male smokers died of
another disease before they could develop cancer. This
explains the negative association between eosinophils and
cancer mortality in the group with the highest risk for
cardiovascular diseases (i.e., male smokers). Finally, a
more mechanistic explanation for the negative association
between eosinophils and cancer is that eosinophils release
cytokines, which may lead to an antitumor response [24]
and produce granule proteins that are highly cytotoxic for
cancer cells [25]. It has also been proposed that a hyper-
active immune function among smokers can detect and
destroy malignant cells which may lead to an inverse
association between allergies and cancer [10].
In our study, IgE was positively associated with lung
cancer mortality among females. This finding may be
explained by the fact that the lung is an organ which is
directly exposed to the noxious stimuli which can be both
allergens and carcinogens. This direct exposure induces
excessive inflammation in allergic subjects which in turn
may promote tumor development (i.e., the antigen stimu-
lation theory may apply here) [14]. However, the gender
difference has not been satisfactorily explained, but that is
a common phenomenon in allergy research [26].
Higher levels of serum total IgE were associated with a
decreased risk of hospitalization due to any cancer among
smokers and males. As mentioned before, this can be a
consequence of male smokers being more prone to develop
lethal cardiovascular diseases. Another explanation may be
that IgE antibodies physiologically survey tumor cells and
eosinophils, and in addition, mast cells and macrophages
can be armed with the cytophilic IgE. These all together
become potent antitumor effectors, able to trace and kill
Table 5 Interaction of
eosinophils, skin test positivity,
and IgE with gender on
mortality risk from any type of
cancer, lung cancer, and
colorectal cancer
Statistically significant results
are shown in bold
Any cancer HR
(95 % CI)
p value Lung cancer HR
(95 % CI)






1.04 (0.91–1.19) 0.551 1.35 (0.89–2.05) 0.159 1.25 (0.84–1.85) 0.272
Effect in
males
1.05 (0.93–1.18) 0.419 1.06 (0.86–1.30) 0.584 0.59 (0.42–0.83) 0.003




0.59 (0.38–0.91) 0.016 0.79 (0.24–2.59) 0.694 0.74 (0.23–2.40) 0.613
Effect in
males
0.97 (0.75–1.26) 0.821 0.92 (0.57–1.48) 0.737 1.55 (0.74–3.22) 0.244




1.18 (0.77–1.80) 0.475 4.64 (1.04–20.70) 0.040 0.68 (0.21–2.19) 0.506
Effect in
males
0.95 (0.73–1.25) 0.659 0.85 (0.50–1.45) 0.611 1.22 (0.57–2.61) 0.638
Interaction 0.81 (0.49–1.33) 0.371 0.18 (0.04–0.90) 0.031 1.79 (0.44–7.23) 0.428
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tumor cells in the tissues [27]. However, evidence shows
that an increased serum total IgE levels may not be
exclusively related with atopic diseases [15].
Some other studies reported both inverse associations
between allergy and cancer as well as positive associations
[7], as we found. Therefore, our findings support the fact
that the association between allergies and cancer is site
specific. According to Sherman’s review, inverse associa-
tions were frequently reported for colorectal cancer,
whereas a positive association was reported for lung cancer
[7].
An important concern in the association between allergy
and cancer is the potential effect modification of gender and
smoking (3). A previous study assessing whether the associ-
ation between history of asthma and/or hay fever and cancer
mortality was modified by gender or smoking showed that the
effect of asthma is more pronounced in males and ever
smokers [28]. Although our results are in accordance with
these findings, the possibility that these interaction results are
confounded, by an unmeasured risk factor for allergy or
cancer, is still of concern and warrants further studies.
Our study has several strengths. First, we investigated
several common types of cancer (lung, colorectal, prostate,
and breast cancer) whereas most other studies focused only
on one specific type of cancer. Second, most previous
studies were cross-sectional in design, whereas our cohort
was followed up for over 40 years. Third, among previous
studies, there is a failure to control for important cancer
and allergy risk factors such as smoking and gender [1].
We studied three biological markers of allergic disease to
operationalize allergy, whereas the majority of previous
studies used questionnaires or investigated associations
between cancer types and asthma, assuming an underlying
atopic constitution that was not tested formally using
objective allergy tests. Finally, a high follow-up rate should
be mentioned, as 99.7 % of the included subjects could be
traced back (Online Resource Table 8).
Hospitalization data were only available since 1995 and
were obtained using probabilistic methods to identify true
matches, which can be subject to error and could be considered
a limitation of our study. Another limitation is that we studied
both cancer mortality and hospital admissions as proxies for
cancer incidence thereby assuming that the mechanisms relat-
ing allergy to cancer incidence do not differ from the mecha-
nisms relating allergy to cancer mortality or hospitalization.
Finally, no information was available on outpatient visits in the
hospitalization data; therefore, we might have missed some
cancer patients who did not require hospitalization.
In conclusion, our results indicate that we failed to
identify overall associations between allergy markers and
cancer. However, we found an inverse association between
eosinophils, skin test positivity, and high serum total IgE
and mortality and hospitalization from different types of
cancer in specific subgroups. Hence, only studies on allergy
and cancer that analyze sub-cohorts defined by gender and
smoking habits may result in the possible identification of
markers of predictive value.
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